BioSpace News Archive

Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer.

Microbiome specialist MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences in the field of metabolic diseases.

Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.

Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.

Biopharma and life sciences companies strengthen their leadership teams and board with this week’s Movers & Shakers.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Here’s a look at the two drugs that had dates this week but were approved early and are now on the market.

Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range

Compugen Ltd. (Nasdaq: CGEN), today announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) and BMS-986207, Bristol-Myers Squibb’s investigational anti-TIGIT antibody.